Intellia Therapeutics, Inc. (NASDAQ:NTLA) had its price target boosted by Credit Suisse Group from $24.00 to $28.00 in a report released on Friday, November 3rd. The firm currently has an outperform rating on the stock.
Several other brokerages have also recently issued reports on NTLA. Jefferies Group LLC set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a buy rating in a report on Tuesday, October 31st. Zacks Investment Research raised Intellia Therapeutics from a sell rating to a hold rating in a research note on Wednesday, October 4th. Leerink Swann raised their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an outperform rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush reissued an ourperform rating and set a $25.00 price objective (down previously from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, ValuEngine raised Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $30.17.
Shares of Intellia Therapeutics (NASDAQ:NTLA) traded up $1.90 during midday trading on Friday, reaching $22.56. 863,708 shares of the company’s stock were exchanged, compared to its average volume of 329,652. Intellia Therapeutics has a twelve month low of $10.83 and a twelve month high of $33.34.
Several institutional investors have recently added to or reduced their stakes in NTLA. GMT Capital Corp bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $8,214,000. Ark Investment Management LLC lifted its position in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after buying an additional 94,960 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after buying an additional 92,580 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $1,132,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $907,000. Institutional investors and hedge funds own 48.89% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with our FREE daily email newsletter.